Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.57 |
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2358262 | 0.90 | KDM4E (0.68) | KDM4ELMNAALDH1A1HSD17B10HPGD | |
| SCHEMBL9262268 | 0.79 | KDM4E (0.66) | KDM4ELMNAALDH1A1HSD17B10HPGD | |
| SCHEMBL2359579 | 0.78 | KDM4E (0.61) | KDM4ELMNAALDH1A1HSD17B10HPGD | |
| SCHEMBL2359348 | 0.76 | AR (0.45) | KDM4ELMNAALDH1A1HSD17B10HPGD | |
| SCHEMBL9265227 | 0.75 | MAPK10 (0.58) | KDM4ELMNAALDH1A1HSD17B10HPGD | |
| SCHEMBL12441033 | 0.74 | AR (0.46) | KDM4ELMNAALDH1A1HSD17B10HPGD | |
| SCHEMBL12440855 | 0.74 | AR (0.50) | KDM4ELMNAALDH1A1HSD17B10HPGD | |
| SCHEMBL12440720 | 0.74 | AR (0.40) | KDM4ELMNAALDH1A1HSD17B10HPGD | |
| SCHEMBL4160282 | 0.72 | LMNA (0.82) | KDM4ELMNAALDH1A1HSD17B10HPGD | |
| SCHEMBL12440431 | 0.72 | KDM4E (0.48) | KDM4ELMNAALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-12-19 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| US-20170121285-A1 | Selective androgen receptor modulators | RADIUS HEALTH INC (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121285-A1 | Selective androgen receptor modulators | RADIUS HEALTH INC (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121285-A1 | Selective androgen receptor modulators | RADIUS HEALTH INC (US) | 2017-05-04 | — | — | US | disclosed |
| EP-2531029-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2531029-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20150266821-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266821-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266821-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-8987319-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987319-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987319-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. | 2013-02-14 | — | — | US | disclosed |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. | 2013-02-14 | — | — | US | disclosed |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. | 2013-02-14 | — | — | US | disclosed |
| WO-2011097496-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC47A1, SLC47A2 | KDM4E 4720/4885LMNA 3829/4885ALDH1A1 1099/4885 |
| US-20170121285-A1 | Selective androgen receptor modulators | AR, SHBG, FSHR | KDM4E 1228/4885LMNA 1424/4885ALDH1A1 1511/4885 |
| US-20150266821-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, SHBG, FSHR | KDM4E 1235/4885LMNA 1414/4885ALDH1A1 1542/4885 |
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | ABCB11, SLC47A1, SLC47A2 | KDM4E 4720/4885LMNA 3829/4885ALDH1A1 1099/4885 |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | AR, SHBG, GPR119 | KDM4E 1925/4885LMNA 1447/4885ALDH1A1 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.